|Bid||19.91 x 800|
|Ask||21.85 x 800|
|Day's Range||20.01 - 20.88|
|52 Week Range||13.42 - 30.90|
|Beta (5Y Monthly)||2.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.20|
Kaplan-Meier estimated survival at one year and two years post treatment with investigational RVT-802 was 77% and 76%, respectively Follow-up time in the Efficacy Analysis Set (EAS) ranged from 0 to 25.5 years; For patients who were alive at one year post treatment, the Kaplan-Meier estimated long-term survival rate was 93% at a median follow-up time of 10.9 years The most common (>3%) adverse reactions occurring in patients treated with investigational RVT-802 were low platelets, neutropenia, f
MYOV earnings call for the period ending June 30, 2021.
Myovant Sciences (NYSE: MYOV) stock is losing ground after the company reported earnings for its fiscal first quarter, the three-month period ended June 30, 2021. Investors upset about net product sales that weren't very impressive led the stock 12.5% lower this morning. Sales of products containing Myovant's gonadotropin-releasing hormone (GnRH) receptor antagonist, Orgovyx (relugolix), weren't as impressive as investors were expecting.